Literature DB >> 1000771

Quantification of baroreceptor influence on arterial pressure changes seen in primary angiotension-induced hypertension in dogs.

A W Cowley, J W DeClue.   

Abstract

We studied the role of the sino-aortic baroreceptors in the gradual development of hypertension induced by prolonged administration of small amounts of angiotensin II (A II) in intact dogs and dogs with denervated sino-aortic baroreceptors. Short-term 1-hour infusions of A II(1.0-100 ng/kg per min) showed that conscious denervated dogs had twice the pressor sensitivity of intact dogs. Long-term infusions of A II at 5.0 ng/kg per min (2-3 weeks) with continuous 24-hour recordings of arterial pressure showed that intact dogs required 28 hours to reach the same level of pressure attained by denervated dogs during the 1st hour of infusion. At the 28th hour the pressure in both groups was 70% of the maximum value attained by the 7th day of infusion. Both intact and denervated dogs reached nearly the same plateau level of pressure, the magnitude being directly related both the the A II infusion rate and the daily sodium intake. Cardiac output in intact dogs initially decreased after the onset of A II infusion, but by the 5th day of infusion it was 38% above control, whereas blood volume was unchanged. Heart rate returned to normal after a reduction during the 1st day of infusion in intact dogs. Plasma renin activity could not be detected after 24 hours of A II infusion in either intact or denervated dogs. The data indicate that about 35% of the hypertensive effect of A II results from its acute pressor action, and an additional 35% of the gradual increase in arterial pressure is in large measure a result of baroreceptor resetting. We conclude that the final 30% increase in pressure seems to result from increased cardiac output, the cause of which may be decreased vascular compliance. since the blood volume remains unaltered.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1000771     DOI: 10.1161/01.res.39.6.779

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  8 in total

1.  Angiotensin II infusion model of hypertension: is there an important sympathetic component?

Authors:  Thomas E Lohmeier
Journal:  Hypertension       Date:  2012-01-23       Impact factor: 10.190

Review 2.  The baroreflex as a long-term controller of arterial pressure.

Authors:  Thomas E Lohmeier; Radu Iliescu
Journal:  Physiology (Bethesda)       Date:  2015-03

Review 3.  Arterial baroreceptor input contributes to long-term control of blood pressure.

Authors:  Terry N Thrasher
Journal:  Curr Hypertens Rep       Date:  2006-06       Impact factor: 5.369

Review 4.  Neural mechanisms of angiotensin II-salt hypertension: implications for therapies targeting neural control of the splanchnic circulation.

Authors:  John W Osborn; Gregory D Fink; Marcos T Kuroki
Journal:  Curr Hypertens Rep       Date:  2011-06       Impact factor: 5.369

5.  Inhibitors of the renin-angiotensin system in experimental hypertension, with a note on the measurement of angiotensin I, II and III during infusion of converting-enzyme inhibitor.

Authors:  J J Morton; J Casals-Stenzel; A F Lever; J A Millar; A J Riegger; M Tree
Journal:  Br J Clin Pharmacol       Date:  1979       Impact factor: 4.335

Review 6.  Blood pressure regulation: every adaptation is an integration?

Authors:  Michael J Joyner; Jacqueline K Limberg
Journal:  Eur J Appl Physiol       Date:  2013-04-05       Impact factor: 3.078

7.  Chronic angiotensin II infusion causes differential responses in regional sympathetic nerve activity in rats.

Authors:  Misa Yoshimoto; Kenju Miki; Gregory D Fink; Andrew King; John W Osborn
Journal:  Hypertension       Date:  2010-01-25       Impact factor: 10.190

8.  Baroreceptor Modulation of the Cardiovascular System, Pain, Consciousness, and Cognition.

Authors:  Heberto Suarez-Roca; Negmeldeen Mamoun; Martin I Sigurdson; William Maixner
Journal:  Compr Physiol       Date:  2021-02-12       Impact factor: 9.090

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.